Kala Pharmaceuticals, Inc. (0JQ2.L)
USD 6.03
(-3.51%)
USD 6.03
(-3.51%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -14.57 Million USD | 47.1% |
| 2022 | -27.54 Million USD | -130.54% |
| 2021 | -11.94 Million USD | -150.52% |
| 2020 | 23.65 Million USD | 50.31% |
| 2019 | 15.73 Million USD | 122.02% |
| 2018 | -71.45 Million USD | 25.5% |
| 2017 | -95.91 Million USD | -167.77% |
| 2016 | -35.81 Million USD | -987.46% |
| 2015 | 4.03 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -17.39 Million USD | -45.99% |
| 2024 Q1 | -11.91 Million USD | 18.23% |
| 2023 Q4 | -14.57 Million USD | 27.07% |
| 2023 FY | -14.57 Million USD | 47.1% |
| 2023 Q3 | -19.98 Million USD | -27.37% |
| 2023 Q1 | -30.36 Million USD | -10.25% |
| 2023 Q2 | -15.68 Million USD | 48.34% |
| 2022 Q2 | 37.28 Million USD | 139.72% |
| 2022 Q4 | -27.54 Million USD | -183.41% |
| 2022 Q3 | -9.71 Million USD | -126.07% |
| 2022 FY | -27.54 Million USD | -130.54% |
| 2022 Q1 | 15.55 Million USD | 230.17% |
| 2021 Q4 | -11.94 Million USD | 31.6% |
| 2021 Q2 | -37.54 Million USD | -44.72% |
| 2021 FY | -11.94 Million USD | -150.52% |
| 2021 Q3 | -17.46 Million USD | 53.47% |
| 2021 Q1 | -25.93 Million USD | -209.67% |
| 2020 Q3 | 55.46 Million USD | 305.65% |
| 2020 Q2 | -26.97 Million USD | 71.71% |
| 2020 Q1 | -95.33 Million USD | -705.9% |
| 2020 FY | 23.65 Million USD | 50.31% |
| 2020 Q4 | 23.65 Million USD | -57.36% |
| 2019 Q4 | 15.73 Million USD | 327.12% |
| 2019 Q2 | -16.33 Million USD | 56.19% |
| 2019 Q1 | -37.27 Million USD | 47.83% |
| 2019 FY | 15.73 Million USD | 122.02% |
| 2019 Q3 | 3.68 Million USD | 122.56% |
| 2018 FY | -71.45 Million USD | 25.5% |
| 2018 Q4 | -71.45 Million USD | -29.87% |
| 2018 Q1 | -80.47 Million USD | 16.09% |
| 2018 Q2 | -71.23 Million USD | 11.48% |
| 2018 Q3 | -55.02 Million USD | 22.76% |
| 2017 FY | -95.91 Million USD | -167.77% |
| 2017 Q4 | -95.91 Million USD | 6.25% |
| 2017 Q3 | -102.3 Million USD | -514.84% |
| 2017 Q2 | -16.64 Million USD | 36.83% |
| 2017 Q1 | -26.34 Million USD | 26.46% |
| 2016 Q4 | -35.81 Million USD | 0.0% |
| 2016 FY | -35.81 Million USD | -987.46% |
| 2015 FY | 4.03 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | -87.11 Million USD | 83.273% |
| Dynavax Technologies Corporation | 106.63 Million USD | 113.665% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 56.537% |
| Perrigo Company plc | 3.32 Billion USD | 100.439% |
| Illumina, Inc. | 1.21 Billion USD | 101.2% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 100.054% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 87.205% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 100.177% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 100.113% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 110.044% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 46.229% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 302.755% |
| Waters Corporation | 1.96 Billion USD | 100.743% |
| Biogen Inc. | 6.28 Billion USD | 100.232% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | -105.239% |
| Evolus, Inc. | 63.7 Million USD | 122.873% |
| Adicet Bio, Inc. | -142 Million USD | 89.739% |
| Cara Therapeutics, Inc. | -9.01 Million USD | -61.624% |
| bluebird bio, Inc. | 108.57 Million USD | 113.422% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 103.177% |
| FibroGen, Inc. | 56.76 Million USD | 125.67% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 101.273% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 309.125% |
| Homology Medicines, Inc. | 18.43 Million USD | 179.037% |
| Geron Corporation | 14.76 Million USD | 198.72% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 100.919% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 107.357% |
| Myriad Genetics, Inc. | 88.1 Million USD | 116.54% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 73.142% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 86.919% |
| Zoetis Inc. | 4.76 Billion USD | 100.306% |
| Abeona Therapeutics Inc. | -10.07 Million USD | -44.693% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 100.695% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 103.847% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 99.848% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 101.382% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 145.702% |
| Verastem, Inc. | -37.27 Million USD | 60.91% |
| Nektar Therapeutics | 210.24 Million USD | 106.931% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 92.707% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 60.406% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 101.505% |
| OPKO Health, Inc. | 230.68 Million USD | 106.317% |
| Exelixis, Inc. | -73.05 Million USD | 80.052% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 108.219% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 89.238% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 90.351% |
| uniQure N.V. | -102.95 Million USD | 85.846% |
| Imunon, Inc. | -4.69 Million USD | -210.091% |
| Blueprint Medicines Corporation | 702.83 Million USD | 102.073% |
| Insmed Incorporated | 721.62 Million USD | 102.019% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 101.055% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 53.32% |
| TG Therapeutics, Inc. | 17.86 Million USD | 181.581% |
| Incyte Corporation | -3.17 Billion USD | 99.541% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 101.903% |